115 / 119
114
Diretrizes AMB
34. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N,
Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study
investigators. Efficacy and safety of ustekinumab, a human interleukin-
12/23 monoclonal antibody, in patients with psoriasis: 52-week results
from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet. 2008 May 17;371(9625):1675-84. PubMed PMID: 18486740.
35. Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A; Japanese
Ustekinumab Study Group. Impact of ustekinumab on health-related
quality of life in Japanese patients with moderate-to-severe plaque